인증 보도자료
-
- Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
- Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. G...
- 02월 02일 15:13
